cancer drugs - names and mechanisms

STUDY
PLAY

Terms in this set (...)

folic acid analog that competitively inhibits DHFR
MTX
inhibits thymidylate synthetase
5-FU
induces free radical formation --> breaks in DNA strands
bleomycin
intercalates in DNA
dactinomycin
generates free radicals and intercalates in DNA
doxorubicin
cross-links DNA
busulfan, cisplatin
crosslinks DNA at guanine N-7. Requires bioactivation by liver.
cyclophosphamide
Requires bioactivation, crosses blood-brain barrier --> CNS, Crosslinks DNA.
carmustine, lomustine
inhibits Topo 2 --> increases DNA degradation
etoposide, teniposide
inhibits Topo 1 + prevents DNA unwinding and replication
irinotecan, topotecan
inhibits ribonucleotide reductase --> DNA synthesis
hydroxyurea
monoclonal Ab against VEGF
bevacizumab, ranibizumab
EGFR receptor tyrosine kinase inhibitor
erlotinib
tyrosine kinase inhibitor of BCR-ABL and c-kit
imatinib
monoclonal Ab against CD20
rituximab
monoclonal Ab against HER2
trastuzumab
small molecular inhibitor of BRAF oncogene + melanoma
vemurafenib
CD52 Ab used for CLL
alemtuzumab
Ab against TNFa
adalimumab, infliximab
Ab against complement protein C5 used for paroxysmal nocturnal hemoglobinuria
eculizumab
Ab against a4-integrin used for MS and Crohns
natalizumab
AB against RANKL used for osteoporosis (inhibits osteoclast maturation - mimics osteoprotegerin)
denosumab
Ab against IgE
omalizumab
Ab against RSV F protein, used for RSV prophylaxis in high-risk infants
palivizumab